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Multiple PKCd Tyrosine Residues Are Required
for PKCd-Dependent Activation of Involucrin
Expression—a Key Role of PKCd-Y311
Ling Zhu1, Chaya Brodie2, Sivaprakasam Balasubramanian1 and Richard L. Eckert1,3
Protein kinase C-delta (PKCd) is a key regulator of human involucrin (hINV) gene expression and is regulated by
tyrosine phosphorylation. However, a comprehensive analysis of the requirement for individual PKCd tyrosine
residues is lacking. We show that multiple tyrosine residues influence the ability of PKCd to increase hINV gene
expression. Mutation of individual PKCd tyrosine residues 52, 64, 155, 187, or 565 does not reduce the ability of
PKCd to increase hINV promoter activity; however, simultaneous mutation of these five tyrosines markedly
reduces activity. Moreover, restoration of any one of these residues results in nearly full activity restoration. It is
significant that phosphorylation of PKCd-Y311 is reduced in the five-tyrosine mutant and that mutation of Y311
results in reduced PKCd activity comparable to that observed in the five-tyrosine mutant. Restoration of any one
of the tyrosine residues in the five-tyrosine mutant restores Y311 phosphorylation and biological activity. In
addition, reduced phosphorylation of endogenous PKCd-Y311 is associated with reduced biological activity.
These findings indicate that PKCd activity requires Y311 and a second tyrosine residue; however, any one of the
several tyrosine residues can serve in the secondary role.
Journal of Investigative Dermatology (2008) 128, 833–845; doi:10.1038/sj.jid.5701103; published online 18 October 2007
INTRODUCTION
The protein kinase C (PKC) family comprises at least 11
isoforms that play an important role in the regulation of cell
growth and differentiation (Dlugosz and Yuspa, 1994; New-
ton, 1997). PKC isoforms are classified into three groups on
the basis of structural differences in the regulatory domains
and differences in cofactor regulation. The classical PKCs
(a, bI, bII, and g) are calcium-, phospholipid-, and diacyl-
glycerol-dependent; the novel PKCs (d, e, Z, y, and m)
are calcium-independent; and the atypical PKCs (z and l) are
calcium- and diacylglycerol-independent (Nishizuka, 1992).
All PKC isoforms consist of an N-terminal regulatory domain
and a C-terminal catalytic domain (Nishizuka, 1992). The
regulatory domain is responsible for the subcellular distribu-
tion and contains domains that determine the ligand response
of the isoform, whereas the catalytic domain contains the site
required for catalytic activity (Steinberg, 2004).
PKC isoforms are important regulators of keratinocyte
function. Epidermal keratinocytes express a, d, e, Z, and z
isofoms (Osada et al., 1990; Dlugosz et al., 1992; Gherzi
et al., 1992; Matsui et al., 1992; Fisher et al., 1993). Human
epidermal keratinocytes undergo a tightly controlled differ-
entiation process that results in the formation of terminal
dead cells called corneocytes. Corneocytes consist of a
stabilized keratin network bounded by an envelope of
covalently crosslinked protein called the cornified envelope
(Nemes and Steinert, 1999). The cornified envelope is
deposited via the action of type I transglutaminase during
the final stages of keratinocyte differentiation. The 68 kDa
human involucrin (hINV) protein is a highly reactive
transglutaminase substrate and component of the scaffold of
the cornified envelope (Nemes and Steinert, 1999). The hINV
gene is expressed in a differentiation-dependent manner—it
is selectively expressed in differentiated suprabasal keratino-
cytes (Rice and Green, 1979; Murphy et al., 1984; Eckert
et al., 1997). We have previously demonstrated that the novel
PKC isoforms, including PKCd, activate keratinocyte differ-
entiation and increase endogenous involucrin gene expres-
sion and hINV promoter activity. This increase is mediated
via a novel PKC, Ras, MEKK1, MEK3, p38d–ERK1/2 signaling
cascade, which results in increased levels of AP1, C/EBP, and
Sp1 transcription factors, increased binding of these factors to
the hINV promoter, and increased gene transcription
(Efimova and Eckert, 2000; Efimova et al., 2002; Eckert
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et al., 2004b). The novel PKCs, including PKCd, also function
with calcium, an agent that increases keratinocyte differ-
entiation, to increase calcium-dependent hINV promoter
activity (Deucher et al., 2002). The regulation by PKCd can
be specifically inhibited by a PKCd inhibitor, rottlerin, and
the increase in promoter activity is associated with increased
levels of hINV mRNA and protein (Efimova and Eckert, 2000;
Efimova et al., 2004). Thus, a physiologic role for PKCd as a
regulator of hINV gene expression is well established.
The effects of tyrosine phosphorylation on the activity of
PKCd are complex and depend on the cell environment and
the presence of specific agonists (Denning et al., 1993, 1996;
Li et al., 1994, 1996). The PKCd amino-acid sequence
includes 19 tyrosine residues, 9 of which have been
identified as sites of phosphorylation (Brodie and Blumberg,
2003). For example, activation of IgE receptors in RBL-2H3
cells leads to phosphorylation of PKCd-Y52 (Szallasi et al.,
1995), and in NIH 3T3 fibroblasts, PKCd-Y187 is phosphory-
lated in response to 12-O-tetradecanoylphorbol-13-acetate
(TPA) or platelet-derived growth factor stimulation (Li et al.,
1996). These changes in phosphorylation state are frequently
associated with altered activity. Phosphorylation of PKCd on
tyrosine residues in v-ras-transformed keratinocytes leads to
reduced catalytic activity (Denning et al., 1993). In contrast,
H2O2 treatment induces phosphorylation on tyrosine residues
311, 332, and 512 of PKCd in COS-7 cells, which is
associated with increased PKCd activity (Konishi et al., 2001).
Our previous studies demonstrate that PKCd expression
enhances calcium-dependent hINV promoter activity; cal-
cium treatment does not alter the expression level or induce
PKCd translocation to membranes, but does cause a marked
increase in PKCd tyrosine phosphorylation (Deucher et al.,
2002). In spite of the importance of tyrosine phosphorylation
on PKCd function, a comprehensive analysis of the role of
specific PKCd tyrosine residues has not been performed. In
this study, we examine the function of individual PKCd
tyrosine residues. Mutation of a single tyrosine residue at
position 52, 64, 155, 187, or 565 does not reduce the ability
of PKCd to drive hINV promoter activity. In contrast,
simultaneous mutation of tyrosines 52, 64, 155, 187, and
565 markedly reduces the response. Interestingly, restoration
of any one of these tyrosine residues restores full activity. In
each case, mutants with high activity are highly phosphory-
lated on Y311, and mutation of Y311 reduces PKCd activity
comparable to the five-tyrosine mutant. In addition, diet-
derived agents (curcumin, apigenin) suppress hINV promoter
activity, and this is associated with reduced phosphorylation
of PKCd-Y311. These novel findings indicate that Y311, and at
least one additional companion tyrosine residue (tyrosine 52,
64, 155, 187 or 565), must be present for PKCd activity in
keratinocytes.
RESULTS
The PKCd protein encodes two major functional domains—
the catalytic domain at the C-terminus and the regulatory
domain at the N-terminus (Steinberg, 2004). To understand
the role of these domains in regulating involucrin gene
expression, we utilized domain-swap mutants. PKCd/a
encodes the PKCd regulatory domain fused to the PKCa
catalytic domain; PKCa/d encodes the PKCa regulatory
domain fused to the PKCd catalytic domain (Blass et al.,
2002). To monitor the impact of the PKC domain-swap
mutants on involucrin gene expression, keratinocytes were
transfected with the involucrin promoter reporter plasmids
indicated in Figure 1a. pINV-2473 encodes the full-length
promoter, whereas pINV-DRR(2473/1953) and pINV-241
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Figure 1. PKCd regulatory domain is required for PKCd activation of hINV
promoter activity. (a) hINV promoter-luciferase reporter gene constructs.
The narrow line represents the hINV promoter sequence and the dark box
represents the luciferase gene. The arrow indicates the start site and the
direction of transcription. The plasmids are named (pINV-2473, pINV-241,
etc.) on the basis of the length of the segment, as measured backward from the
hINV transcription start site (Eckert and Green, 1986). The scale at the top is in
nucleotides. (b) Twenty-five percent confluent keratinocytes were transfected
with 1 mg of the indicated involucrin promoter reporter plasmidþ1 mg of
empty expression vector (EV) or plasmids encoding PKCa, PKCd, PKCa/d, or
PKCd/a. At 48 hours post-transfection, the cells were harvested and lysed for
luciferase activity assay. The results depict the mean7SEM, n¼ 4.
(c) Detection of expressed proteins. Keratinocytes were transfected with 1 mg
of empty vector (EV) or plasmid encoding the indicated protein. After
48 hours, the cells were harvested and total cell extracts were prepared for
electrophoresis and immunodetection of the C-terminus of PKCd, the
C-terminus of PKCa, and b-actin.
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encode the distal and proximal regulatory region, respec-
tively (Welter et al., 1995). These constructs were selected
because they encode regulatory domains that are known to
respond in a positive manner when keratinocytes are treated
with agents that enhance keratinocyte differentiation (Eckert
et al., 2004b). pINV-41 encodes the minimal promoter and is
not regulated by keratinocyte differentiation agents (Welter
et al., 1995). Keratinocytes were transfected with these
plasmids in the absence or presence of plasmids encoding
PKCd, PKCa, PKCd/a, and PKCa/d, and luciferase activity was
monitored at 48 hours post-transfection. As shown in Figure
1b, expression of PKCd and PKCd/a increase the activity of all
three reporter constructs. In contrast, PKCa and PKCa/d do
not increase activity. None of the PKC expression constructs
increases the activity of pINV-41, the hINV minimal promoter
plasmid. Figure 1c shows that the key mutants are expressed
at a level that permits direct comparison. PKCa and PKCd/a
are present at equal levels, but only PKCd/a is active—
indicating that the PKCd regulatory domain confers activity
on the PKCa backbone. Likewise, the PKCd/PKCa/d compar-
ison is also well controlled regarding expression level—in
this case, PKCa/d is not active. These findings are consistent
with our previous report indicating that PKCd increases hINV
gene expression and that PKCa is not active (Deucher et al.,
2002) and suggest that the PKCd regulatory domain is
required for the PKCd regulation.
We next monitored the impact of selective mutation of
PKCd tyrosine residues on the ability to drive hINV gene
expression. Keratinocytes were transfected with each of the
involucrin promoter reporter constructs shown in Figure 1a in
the presence of the wild-type or mutated PKCd. As shown in
Figure 2a, changing PKCd tyrosine 52, 64, 155, 187, or 565
to phenylalanine does not attenuate PKCd-dependent hINV
promoter activity. However, reduced activity is observed
when all five tyrosine residues are simultaneously mutated,
suggesting that a global reduction in tyrosine residue density
is required to attenuate biological response. As all three of
the hINV promoter constructs respond in a similar fashion,
we subsequently focused on only one of the constructs,
pINV-241.
The fact that eliminating five tyrosine residues results in a
substantial loss of activity suggests that one or more of these
tyrosines may be essential for function. To identify essential
PKCd tyrosine residue(s), we systematically restored indivi-
dual tyrosines in the context of the PKCd-D5 mutant. To our
surprise, as shown in Figure 3b, restoration of any single
tyrosine residue (tyrosine 52, 64, 155, 187, or 565) or
simultaneous restoration of two residues results in a near-
complete restoration of activity, suggesting that no particular
tyrosine residue is essential for biological activity. Figure 3a
shows that each PKCd mutant is expressed at a comparable
level.
Role of PKCd-Y311
PKCd-Y311 has been implicated as being required for
PKCd biological activity in human epidermal keratinocytes
(Denning et al., 1995, 1998; Deucher et al., 2002; Efimova
et al., 2002). We next inquired whether the effects of
mutating the various tyrosine residues may be mediated via
an impact on Y311 phosphorylation. To test this hypothesis,
we transfected keratinocytes with pINV-241 in the presence
or absence of PKCd, PKCd-Y311F, PKCd-D5, or PKCd-D6
(PKCd-D6 is identical to PKCd-D5, except that Y311 is also
mutated). As shown in Figure 4a, the PKCd-wt-dependent
increase in promoter activity is substantially reduced for the
PKCd-Y311F, PKCd-D5, and PKCd-D6 mutants. As shown in
Figure 4b, this decrease in activity is associated with reduced
phosphorylation of Y311 for all three mutants. It is important
to note that the anti-P-Y311 antibody detects residual
phosphorylation, presumably because it is not entirely
specific for Y311 (Rybin and Steinberg, 2006). These findings
demonstrate that mutation of Y311 creates a protein with
reduced biological activity. Moreover, these findings indicate
that the reduced activity of PKCd-D5 is associated with
reduced Y311 phosphorylation.
The above findings show that elimination of five tyrosine
residues in PKCd results in a marked reduction in the
functional activity (Figure 3), which is associated with
reduced phosphorylation at Y311 (Figure 4). This suggests
that the status of tyrosines 52, 64, 155, 187 and 565 may
pINV-2473 pINV-DRR
(–2473/–1953)
pINV-241pINV-41
PKC
PKC-Y52F
PKC-Y64F
PKC-Y155F
PKC-Y187F
PKC-Y565F
PKC-Δ5(Y52,64,155,187,565F)
EV
PK
C
PKC
PK
C
-
Y 52
F
PK
C
-
Y 64
F
PK
C
-
Y 15
5F
PK
C
-
Y 18
7F
PK
C
-
Y 56
5F
PK
C
-
Δ5
(Y 52
,64
,15
5,1
87
,56
5F
)
EVC
129
82
45 -Actin
0
2
4
6
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (×
10
0) 
pe
r 
g 
pr
ot
ei
n
Figure 2. Impact of tyrosine mutation on the ability of PKCd to drive
hINV promoter activity. (a) Twenty-five percent confluent keratinocytes
were transfected with 1 mg of indicated involucrin promoter reporter
plasmidþ 1 mg of empty expression vector (EV) or plasmids encoding PKCd,
PKCd-Y52F, PKCd-Y64F, PKCd-Y155F, PKCd-Y187F, PKCd-Y565F, or PKCd-
D5(Y52,64,155,187,565F). At 48 hours post-transfection, the cells were harvested
and lysed for luciferase activity assay. The results show the mean7SEM,
n¼ 6. (b) Detection of expressed PKCd proteins. Keratinocytes were
transfected with 1 mg of empty expression plasmid (EV) or plasmid encoding
the indicated PKCd protein. After 48 hours, the cells were harvested and total
cell extracts were prepared for electrophoresis and immunodetection of
vector-delivered PKCd using anti-PKCd.
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influence phosphorylation at Y311. To assess this, keratino-
cytes were transfected with the PKCd mutants shown in
Figure 5a in which individual tyrosine residues were restored
and the level of phosphorylation at PKCd-Y311 was monitored
by immunoblot, as was the total expression level of each
PKCd form (Figure 5b). To assess the relative level of PKCd-
Y311 phosphorylation, the blots were scanned and the relative
level of Y311 phosphorylation was expressed relative to the
total level of protein present (Figure 5c). This analysis reveals
that reduced Y311 phosphorylation is observed for PKCd-
D5(Y52,64,155,187,565F), PKCd-D6(Y52,64,155,187,311,565F), and
PKCd-Y311. In addition, it is interesting that restoration
of tyrosine 52, 64, or 565 restores phosphorylation at Y311.
A similar normalization of Y311 phosphorylation is observed
following restoration of tyrosine 187 or 565 or when paired
sets of tyrosine residues are restored (not shown).
Reduced PKCd-Y311 phosphorylation is associated with reduced
activity
To determine the impact of reduced PKCd-Y311 phosphoryla-
tion on PKCd activity, keratinocytes were transfected with
plasmids encoding wild-type PKCd and mutant PKCd proteins
as green fluorescent protein (GFP) fusions. After 48 hours,
total extracts were prepared and individual PKCd-GFP fusion
proteins were precipitated using anti-GFP. The precipitated
PKCd forms were then monitored for kinase activity as
measured by the ability of each to catalyze the incorporation
of radioactive phosphate into serine on a PKCd substrate
peptide. As shown in Figure 6a, the PKCd-Y311F, PKCd-D5,
and PKCd-D6 mutants display reduced activity relative to
wild-type PKCd and the PKCd-Y52F and PKCd-D4 mutants.
Figure 6b shows the level of endogenous and expressed
PKCd and PKCd-GFP present in the transfected cells. The
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Figure 3. Restoration of one or two tyrosine residues in the PKCd-D5 mutant
restores hINV promoter activity. (a) Expression of vector-delivered proteins.
Keratinocytes were transfected with 1 mg of empty plasmid vector (EV) or
plasmid encoding the indicated protein. After 48 hours, the cells were
harvested and total cell extracts were prepared for electrophoresis and
immunodetection of vector-delivered PKCd. (b) Twenty-five percent confluent
keratinocytes were transfected with 1 mg of pINV-241 promoter reporter
plasmidþ 1 mg of empty expression vector (EV) or the indicated PKCd-
encoding plasmid. At 48 hours post-transfection, the cells were harvested and
lysed for luciferase activity assay. The results show the mean7SEM, n¼4.
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Figure 4. Phosphorylation level of PKCd and PKCd tyrosine mutants at Y311.
(a) Keratinocytes were transfected with 1 mg of pINV-241 plus 1 mg of EV or
plasmid encoding the indicated protein. After 48 hours, the cells were
harvested and total cell extracts were prepared for luciferase activity assay.
Results show the mean7SEM, n¼ 3. (b) Keratinocytes were transfected with
1mg of the indicated construct. After 48 hours, extracts were prepared and the
level of phosphorylated PKCd-Y311 and total PKCd was monitored by
immunoblot. b-Actin level was monitored as a control to normalize gel
loading.
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immunoblot, in the upper panel, indicates that each PKCd-
GFP fusion protein is expressed at a comparable level. The
lower panel indicates the amount of PKCd-GFP precipitated
in each group. The level of precipitation of each respective
mutant varied by twofold among experiments. However, the
activity normalized to the amount of PKCd present yielded
results similar to Figure 6a in each of three separate
experiments. Figure 6b also indicates that the precipitates
are not contaminated with endogenous PKCd. These findings
indicate that PKCd-Y311F, PKCd-D5, and PKCd-D6 have
partially reduced activity as compared to wild-type PKCd;
however, none of the mutations completely inactivate the
kinase.
Subcellular localization
As PKCd, PKCd-D5, and PKCd-Y311F have GFP fused at the
PKC C-terminus, we were able to directly monitor subcellular
distribution by confocal microscopy. Keratinocytes were
transfected with plasmids encoding PKCd-GFP, PKCd-D5-
GFP, PKCd-Y311F-GFP, or GFP. After 48 hours, the cells were
treated for 0–60minutes with 50 ng ml1 TPA and then fixed
for confocal visualization. As shown in Figure 7a, wild-type
PKCd is distributed in the cytoplasm of untreated cells and
appears at the plasma membrane beginning at 5minutes
following TPA treatment, and by 15 and 30minutes it also
appears at a perinuclear location. By 60minutes, most of the
PKCd is present either at the plasma membrane or at the
perinuclear location. A similar pattern of redistribution is
observed for PKCd-D5 and PKCd-Y311F. Figure 7b is a control,
which shows that GFP does not change compartments
following treatment with TPA.
In each case, the shift in subcellular localization was
confirmed by biochemical analysis. In this experiment,
keratinocytes were transfected with PKCd, PKCd-Y311F, and
PKCd-D5. After 48 hours, the cells were treated with 50 ng
ml1 TPA for 60minutes. Figure 8a shows the subcellular
distribution of transfected PKCd forms (present as GFP fusion
proteins) and endogenous PKCd. In cells maintained in the
absence of TPA, all of the PKCd forms distribute equally
between the soluble and particular fractions. In contrast, in
cells treated with TPA, the ratio of each PKCd form is
threefold enriched in the particulate fraction. Thus, the
distribution in resting cells and the pattern of redistribution
following TPA treatment is identical for PKCd and the PKCd-
D5 and PKCd-Y311F mutants, indicating that a change in
subcellular distribution of the mutants does not explain their
reduced activity. As a control for the cell fractionation
protocol, Figure 8b shows that involucrin is, as expected,
present in the soluble fraction (Rice and Green, 1979; Eckert
et al., 1993). The involucrin distribution does not change in
TPA-treated cells (not shown).
PKCd-P-Y311 is reduced by treatment with biological agents
We next examined the impact of agents that suppress
involucrin gene expression on the level of PKCd-P-Y311. We
recently identified curcumin and apigenin as agents that
suppress hINV promoter activity (Balasubramanian et al.,
2006). As shown in Figure 9a, treatment with these agents
reduces the PKCd-dependent increase in hINV promoter
activity to near control levels. Figure 9b shows that this
reduction is associated with reduced phosphorylation of the
expressed PKCd at Y311. We next monitored the impact of
treatment with these agents on endogenous PKCd-P-Y311
level. Figure 9c shows that Y311 phosphorylation of endo-
genous PKCd is also reduced following treatment with
curcumin or apigenin.
PKCd-Y311 phosphorylation is inhibited by src kinase inhibitor
Src is a tyrosine kinase that has been reported to regulate
PKCd tyrosine phosphorylation (Kajimoto et al., 2001, 2004;
Rybin et al., 2004; Kaul et al., 2005; Murugappan et al.,
2005). To determine whether PKCd-Y311 phosphorylation is
regulated by src family kinases in human keratinocytes, we
monitored the impact of treatment with the general src family
inhibitor, PP2, on PKCd-Y311 phosphorylation and promoter
activity. As shown in Figure 10a, treatment with PP2 inhibits
the PKCd-dependent increase in hINV promoter activity.
Moreover, as shown in Figure 10b, this PP2-dependent
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Figure 5. Impact of restoration of tyrosine residues on Y311 phosphorylation.
(a) Structure of PKCd tyrosine mutants. The overall structure of PKCd is
indicated, including the regulatory and catalytic domains and the hinge
region. The locations of the C1, C2, C3, and C4 domains are indicated, as are
the positions of the tyrosine residues targeted (tyrosines 52, 64, 155, 187, 311,
and 565) in this study. (b) Impact of tyrosine mutations on Y311
phosphorylation. Keratinocytes were transfected with EV or plasmids
encoding the indicated PKCd proteins. After 48 hours, the cells were
harvested and the total level of each protein and the extent of phosphorylation
at Y311 were assessed by immunoblot. (c) Ratio of Y311 phosphorylation to
total PKCd. The blots shown in (b) were scanned and the results expressed as a
ratio of PKCd-P-Y311 to total PKCd. Similar phosphorylation differences were
observed in each of the four independent experiments.
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reduction in activity is associated with reduced phosphoryla-
tion of PKCd at Y311 and also reduced residual phosphoryla-
tion of the PKCd-P-Y311F mutant. b-Actin levels are not
changed by PP2 treatment. This finding indicates that
reduced phosphorylation of PKCd-Y311 is associated with
reduced hINV promoter activity.
If this regulation is physiologically relevant, we would
anticipate that Y311 phosphorylation of endogenous PKCd
should also be controlled by src family kinases. To test this,
we monitored the impact of PP2 treatment on hydrogen
peroxide-dependent phosphorylation of PKCd-Y311. H2O2
treatment is known to promote phosphorylation of PKCd on
Y311 (Deucher et al., 2002; Efimova et al., 2004; Kraft et al.,
2006). As shown in Figure 10c, pretreatment with PP2
inhibits the H2O2-dependent phosphorylation, suggesting
that the phosphorylation of Y311 of endogenous PKCd is also
src family kinase-dependent.
Regulation of endogenous involucrin levels
We previously showed that expression of PKCd or other novel
PKC isoforms in keratinocytes results in an increase in
involucrin protein level (Efimova and Eckert, 2000). To assess
the impact of individual PKC mutants on endogenous
involucrin, keratinocytes were transfected with each of the
indicated PKC forms, and hINV protein levels were mon-
itored at 48 hours post-transfection by immunoblot. Figure
11a shows that wild-type PKCd increases hINV level as
compared to empty vector (EV)-transfected cells, but that the
PKCd phosphorylation site mutants (PKCd-Y311F, PKCd-D5,
and PKCd-D6) produced a minimal change in expression. We
also compared the PKC domain-swap mutants for their ability
to regulate involucrin level. These studies indicate that PKCd
and PKCd/a increase hINV level, but that PKCa and PKCa/d
do not (Figure 11b).
DISCUSSION
PKC family members are important regulators of cell
differentiation and survival (Denning et al., 1995; Deucher
et al., 2002; Cataisson et al., 2003; Efimova et al., 1998,
2004). Activity of these kinases is influenced by subcellular
localization, tyrosine phosphorylation, enzymatic processing,
and the presence of other PKC isoforms (Denning et al., 1998;
Mandil et al., 2001; Deucher et al., 2002; Brodie and
Blumberg, 2003; Cataisson et al., 2003; Efimova et al., 2002,
2004; Steinberg, 2004; D’Costa and Denning, 2005; D’Costa
et al., 2005; Li et al., 2006). In recent years, it has been
appreciated that phosphorylation is an important mechanism
that regulates PKCd function (Brodie and Blumberg, 2003;
Steinberg, 2004). PKCd is sequentially phosphorylated on
serine residues as part of the protein maturation process
(Brodie and Blumberg, 2003; Steinberg, 2004). However,
tyrosine phosphorylation is responsible for regulating activity
(Brodie and Blumberg, 2003; Steinberg, 2004). Previous
studies in a number of cell types indicate that PKCd is tyrosine
EV PK
C
PKC-GFP
PKC-GFP
-Actin
IB: anti-PKC
IB: anti-PKCIP: anti-GFP
PKC (endogenous)
PKC (endogenous)
PK
C
-
Y 5
2F
PK
C
-
Y 3
11
F
PK
C
-
Δ4
(Y 6
4,
15
5,
18
7,
56
5F
)
PK
C
-
Δ5
(Y 5
2,
64
,1
55
,1
87
,5
65
F)
PK
C
-
Δ6
(Y 5
2,
64
,1
55
,1
87
,3
11
,5
65
F)
PK
C
PK
C
 
a
ct
iv
ity
 (p
mo
l A
TP
 m
in
–
1 )/
PK
Cδ
 
le
ve
l
PK
C
-
Y 5
2F
PK
C
-
Y 3
11
F
PK
C
-
Δ4
(Y 6
4,
15
5,
18
7,
56
5F
)
PK
C
-
Δ5
(Y 5
2,
64
,1
55
,1
87
,5
65
F)
PK
C
-
Δ6
(Y 5
2,
64
,1
55
,1
87
,3
11
,5
65
F)
129
129
82
82
45
35
30
25
20
15
10
5
0
Figure 6. PKCd activity assay. (a) Mutants with reduced phosphorylation of PKCd-Y311 have reduced activity. Keratinocytes in 3 60mm dishes were
transfected with 3 mg per dish of the indicated plasmid. After 48 hours, the PKCd-GFP fusion protein was precipitated from 400 mg of total protein with anti-GFP
(ab1218), and the precipitated PKCd-GFP proteins were assayed for kinase activity. The precipitate was resuspended in 20 ml of kinase buffer, and 5 ml was used
in the kinase reaction. Details of this method are provided in the text. Background kinase activity, in the EV control group, was negligible (0.3 pmol ATP
minute1). Similar results were observed in each of the three experiments. The results are presented as PKCd activity normalized to PKCd level (pmol ATP per
minute per PKCd level). (b) PKCd-GFP immunoprecipitation. Keratinocytes were transfected with wild-type and mutant PKCd forms as indicated. After 48 hours,
total cell lysate (upper panel) and anti-GFP immunoprecipitates (lower panel) were electrophoresed and immunoblotted with anti-PKCd. The expected migration
position of endogenous PKCd is shown. It is important to note that it is not precipitated (see EV lane) by anti-GFP and therefore does not contribute to the PKC
activity assay. Similar results were observed in three separate experiments.
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phosphorylated by src family kinases (Kajimoto et al., 2001,
2004; Rybin et al., 2004; Kaul et al., 2005; Murugappan
et al., 2005) and by c-abl (Lu et al., 2006). The target tyrosine
residues on PKCd vary in different cell types and in response
to different stimuli (Li et al., 1996; Acs et al., 2000; Dundr
et al., 2000; Kronfeld et al., 2000; Blass et al., 2002; Zrachia
et al., 2002; Okhrimenko et al., 2005; Lu et al., 2006).
PKCd tyrosine phosphorylation in keratinocytes
PKCd tyrosine phosphorylation status alters PKCd activity and
downstream responses in keratinocytes. Increased PKCd
tyrosine phosphorylation is associated with reduced PKCd
activity in ras-transformed murine keratinocytes (Yuspa et al.,
1994; Denning et al., 1993, 1996). This reduction is
associated with reduced cell differentiation (Joseloff et al.,
2002) and is reversed by general tyrosine kinase inhibitors
(Reynolds et al., 1993) and src kinase inhibitors (Joseloff
et al., 2002). In this same cell type, differentiation is
stimulated when PKCd-Y64F or PKCd-Y565F mutants are
expressed, suggesting that phosphorylation of these residues
may result in reduced PKCd activity (Joseloff et al., 2002). In
contrast, PKCd-Y52F, PKCd-Y155F, and PKCd-Y187F do not
induce differentiation. Thus, in v-ras-transformed murine
keratinocytes, increased PKCd tyrosine phosphorylation,
possibly at tyrosines 64 and 565, is associated with decreased
kinase activity and reduced cell differentiation (Denning
et al., 1993).
In contrast, in normal murine keratinocytes, treatment
with the differentiation agent calcium results in increased
PKCd tyrosine phosphorylation, and this increase is asso-
ciated with enhanced differentiation (Denning et al., 2000).
Treatment with EGF or TGFa, which activate src family
kinases, also leads to enhanced PKCd phosphorylation and
enhanced differentiation (Denning et al., 1996). Thus, in
contrast to the situation in ras-transformed murine keratino-
cytes, in normal murine keratinocytes, increased PKCd
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Figure 7. Subcellular distribution of PKCd mutants in keratinocytes. (a) Distribution of PKCd-GFP fusion proteins in keratinocytes. Keratinocytes, growing on
glass coverslips, were transfected with plasmids encoding the indicated PKCd forms, each having GFP fused to the C-terminus. After 48 hours, the cells were
treated with 50 ng ml1 TPA for the indicated time and then harvested and fixed. The distribution of EGFP fluorescence was then examined by confocal
microscopy. (b) The distribution pattern of EGFP. The lower panel shows the distribution pattern of GFP in cells transfected with pEGFP-N1. No change in
distribution was observed in response to treatment with TPA.
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tyrosine phosphorylation is associated with enhanced kera-
tinocyte differentiation. PKCd phosphorylation has also been
studied in normal human keratinocytes. Calcium treatment of
normal human keratinocytes results in increased tyrosine
phosphorylation of PKCd, and PKCd and calcium act
synergistically to increase differentiation as measured by
increased involucrin gene expression (Deucher et al., 2002).
PKCa antagonizes this action (Deucher et al., 2002). PKCd is
known to be phosphorylated on Y311 in these cells (Efimova
et al., 2004), and this phosphorylation is increased following
treatment with the apoptosis-inducing agent, hydrogen
peroxide (Kraft et al., 2006). In contrast, the differentiating
agent okadaic acid does not increase PKCd phosphorylation
at Y311 (Kraft et al., 2006). Thus, information on the role of
specific PKCd tyrosine residues in keratinocytes is limited.
A PKCd five-tyrosine mutant has reduced ability to regulate
involucrin gene expression
In this study, we examined the impact of PKCd tyrosine
phosphorylation on PKCd-dependent regulation of involucrin
gene expression in normal human keratinocytes. Involucrin is
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Figure 8. Redistribution of PKCd and PKCd mutants in TPA-treated
keratinocytes. (a) Twenty-five percent confluent cultures of keratinocytes
were transfected with 3 mg of EV (pEGFP-N1) or plasmids encoding PKCd,
PKCd-Y311F, or PKCd-D5. Each of the transfected PKCd forms included GFP
fused at the PKCd C-terminus. After 48 hours, the cells were treated for
60minutes in the presence or absence of 50 ng ml1 TPA. Soluble and
particulate (membrane) fractions were prepared and the distribution of
transfected and endogenous PKCd was monitored by immunoblot using anti-
PKCd. (b) Involucrin distributes in the soluble fraction. Keratinocytes were
treated as above and then hINV level was monitored using anti-hINV. It
should be noted that these samples were loaded on the basis of total protein
concentration and that, if the samples were loaded on the basis of cell
equivalents, the amount of membrane-associated PKCd and hINV would be
decreased threefold.
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Figure 9. Increased phosphorylation of PKCd-Y311 is associated with increased ability to PKCd to increase hINV promoter activity. (a) Twenty-five percent
confluent keratinocytes were transfected with 1 mg of hINV-241þ 1 mg of empty expression vector (EV) or 1 mg of the indicated PKCd-encoding plasmid. At
24 hours post-transfection, the cells were treated with apigenin or curcumin for an additional 24 hours and then harvested and lysed for luciferase activity assay.
The results show the mean7SEM, n¼ 4. (b) Keratinocytes were transfected with 1 mg of EV or the indicated PKCd-encoding plasmid. After 24 hours, the cells
were treated with apigenin or curcumin for an additional 24 hours. Total cell extracts were prepared for immunodetection of vector-expressed total PKCd and
phosphorylated PKCd-Y311. (c) Apigenin and curcumin suppress Y311 phosphorylation of endogenous PKCd. Keratinocytes were incubated with 20 mM curcumin
or apigenin for 24 hours. Total extracts were prepared and electrophoresed, and total PKCd and tyrosine-phosphorylated PKCd were detected by immunoblot.
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a marker of keratinocyte differentiation that is expressed in
the suprabasal epidermal layers (Robinson et al., 1996; Eckert
et al., 1993, 1997). Our previous studies show that a PKCd,
Ras, MEKK1, MEK3 pathway that acts via an ERK1/2–p38d
complex regulates differentiation in keratinocytes (Efimova
and Eckert, 2000; Efimova et al., 1998, 2002, 2003).
Activation of this pathway ultimately results in increased
AP1, Sp1, and C/EBP transcription factor binding to the hINV
promoter upstream regulatory region and increased gene
expression (Efimova and Eckert, 2000; Efimova et al., 1998,
2002, 2003).
Our studies show that mutation of individual tyrosine
residues at position 52, 64, 155, 187, or 565 does not reduce
the ability of vector-expressed PKCd to increase hINV
promoter activity. However, simultaneous mutation of all
five residues results in a substantial loss of the ability to
increase hINV promoter activity and endogenous hINV
protein level. It is also informative that restoration of any
one of these residues results in the complete restoration of
PKCd function. This is surprising, as we had anticipated that
only selected tyrosines would be important. In C6 glioma
cells, etoposide treatment causes apoptosis, a response that is
inhibited when the PKCd-D5 mutant is expressed (Blass et al.,
2002). Mutation of individual PKCd tyrosine residues in this
cell type indicates that tyrosines 64 and 187 are required for
etoposide-dependent apoptosis (Blass et al., 2002). This is
clearly a different situation from this study, where restoration
of any of the five PKCd tyrosine residues restores biological
activity.
PKCd-Y311 has a key role
To extend these studies, we examined the role of PKCd-Y311.
Phosphorylation at PKCd-Y311 is known to be regulated in
keratinocytes. Hydrogen peroxide treatment increases PKCd-
Y311 phosphorylation and causes apoptosis/differentiation
(Efimova et al., 2004), whereas treatment with the dietary
chemopreventive agent, apigenin, decreases PKCd-Y311 phos-
phorylation and suppresses differentiation (Balasubramanian
et al., 2006). Therefore, we decided to assess whether the
reduction in the activity of the five-tyrosine mutant could be
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Figure 10. Src family kinase inhibitor reduces hINV promoter activity and PKCd-Y311 phosphorylation. (a) Twenty-five percent confluent keratinocyte cultures
were transfected with 1 mg of pINV-41 or pINV-241 plus 1 mg of empty expression vector (EV) or plasmids encoding PKCd-wt, PKCd-D5(Y52,64,155,187,565F), or
PKCd-D6(Y52,64,155,187,311,565F). After 12 hours, the cells were treated with 0 or 5 mM PP2. After an additional 36 hours, the cells were harvested for assay of
luciferase activity. The results show the mean7SEM, n¼ 3. (b) PP2 treatment suppresses phosphorylation of transfected PKCd-Y311. Keratinocytes were treated
with 10 mM PP2 for 60minutes followed by transfection with 2 mg of PKCd-wt or PKCd-Y311F. After 24 hours, the cells were harvested for assay of PKCd-P-Y311
and total PKCd level by immunoblot. (c) PP2 treatment suppresses phosphorylation of endogenous PKCd at Y311. Keratinocytes were pretreated for 60minutes
with 10 mM PP2 and then treated for 0–120minutes with 10mM H2O2. At the indicated times, the cells were harvested and assayed for b-actin, total PKCd, and
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Figure 11. Impact of PKCd mutants on the levels of endogenous involucrin
protein. (a and b) Subconfluent cultures of normal human keratinocytes
were transfected with 2 mg of EV or vector encoding the indicated PKCd
form per 10 cm2 dish. At 48 hours post-transfection, the cells were harvested
and extracts separated by electrophoresis and immunoblotted with
anti-involucrin.
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due to a change in Y311 phosphorylation. This analysis
revealed a surprising role for Y311. First, the results showed
that reduced ability of PKCd-D5(Y52,64,155,187,565F) to drive
involucrin gene expression is associated with reduced
phosphorylation of Y311. Second, restoration of any one of
the five-tyrosine residues permits not only phosphorylation at
Y311 but also PKCd-dependent activation of involucrin gene
expression. Finally, the reduction in functional activity of the
PKCd-D5 mutant is comparable to that observed upon mutation
of Y311. As an additional confirmation, we monitored the impact
of these mutations on PKCd activity. This analysis revealed that
each PKCd mutant that displayed reduced ability to increase
hINV promoter activity also displayed reduced PKCd-Y311
phosphorylation and reduced functional kinase activity. Thus,
Y311 is required for PKCd function.
These findings indicate that any one of the five tyrosine
residues, from among tyrosines 52, 64, 155, 187, and 565,
can partner with Y311. The mechanistic basis for this
observation is not known. It is possible that one of these
tyrosines must be present to provide a docking site for the
tyrosine kinase that phosphorylates PKCd at Y311. Alterna-
tively, phosphorylation of Y311 plus phosphorylation of one of
these other tyrosine may be required to activate PKCd. We
presently favor the latter hypothesis.
Phosphorylation of PKCd-Y311 is functionally important in
other systems and this residue is a target of src family kinases.
Src family kinase-dependent phosphorylation of PKCd-Y311 is
associated with increased thromboxane A2 production in
platelets (Murugappan et al., 2005). Src family kinase-
dependent PKCd-Y311 phosphorylation is also observed in
cardiomyocytes, following treatment with TPA or hydrogen
peroxide (Rybin et al., 2004), and in hydrogen peroxide-
treated dopaminergic neuronal cells (Kaul et al., 2005).
Treatment of HeLa cells with ceramide results in apoptosis,
which is associated with PKCd activation and phosphoryla-
tion at Y311 and Y322 (Kajimoto et al., 2004). Hydrogen
peroxide treatment results in PKCd phosphorylation on
tyrosine residues 311, 332, and 512 in COS-7 cells (Konishi
et al., 2001). Our present studies indicate that src kinase is
important for phosphorylation of PKCd-Y311 in human
keratinocytes, as treatment with src kinase inhibitor reduces
the phosphorylation level. This is consistent with the role of
src kinases in phosphorylating PKCd in murine keratinocytes
(Joseloff et al., 2002).
Subcellular distribution does not have an impact
One possible explanation for the reduced biological activity
of the PKCd-Y311F, PKCd-D5, and PKCd-D6 mutants is an
impact of the mutation on the subcellular distribution of the
PKCd form. This is an important issue, as PKC isoforms are
known to redistribute in response to treatment with physio-
logical agents, and this is thought to be important for
biological activity. For example, PKCd has been reported to
move to the particulate insoluble fraction in murine
keratinocytes (Denning et al., 1995). We therefore examined
whether the PKCd-Y311F, PKCd-D5, or PKCd-D6 mutants
display an altered distribution compared to wild-type PKCd.
In resting cells, all mutants displayed a similar cytoplasmic
distribution, with some also present in the membrane
fraction. Following treatment with TPA, each of the mutants
moves to the plasma membrane and perinuclear region on a
similar time course, a change that is confirmed by biochem-
ical fractionation studies. Thus, there appears to be no
difference in the behavior of these mutants with respect to
intracellular distribution and stimulus-dependent movement,
suggesting that an altered intracellular distribution is not
likely to explain the altered biological activity of the mutants.
An essential role for the PKCd regulatory domain
An additional point of importance is the observation that the
PKCd regulatory domain is required for PKCd activity in
keratinocytes. This is supported by data obtained from
experiments using domain-swap mutants, which show that
PKCd/d and PKCd/a are active whereas PKCa/a and PKCa/d
are not active. This suggests that tyrosine 565 in the PKCd
catalytic domain (see Figure 6) can be substituted by tyrosines
in the PKCa catalytic domain, but that features of the PKCd
regulatory domain are uniquely required for activity. Addi-
tional studies will be required to identify these feature(s).
These findings are in contrast to those reported in C6 glioma
cells, where both the PKCd regulatory and catalytic domains
are required for function (Blass et al., 2002).
Y311 is a physiologically important residue
The above studies indicate that mutation of Y311 to
phenylalanine results in reduced ability of vector-delivered
PKCd to drive involucrin promoter activity and increase
endogenous involucrin protein level. However, an important
aspect is the response of the system following treatment with
physiological or pharmacologic agents. To assess this, we
treated keratinocytes with several agents that suppress
involucrin gene expression. An example is the treatment of
keratinocytes with dietary chemopreventive agents. These
agents suppress keratinocyte differentiation and reduce
involucrin gene expression (Balasubramanian et al., 2006;
Eckert et al., 2004a, 2006). The studies described in this
report indicate that these agents also suppress phosphoryla-
tion of PKCd at Y311. Thus, following treatment with
exogenous dietary agents, PKCd-Y311 phosphorylation is
suppressed, and this is associated with reduced involucrin
gene expression. A particularly good example of this response
is the ability of the dietary-constituent, apigenin, to reduce
PKCd-Y311 phosphorylation. Additional evidence of a phy-
siological role for this tyrosine is the loss of PKCd-dependent
activation of involucrin gene expression in PKCd-Y311
mutants (Balasubramanian et al., 2006). These results are
consistent with a general hypothesis that PKCd-dependent
activation of keratinocyte differentiation requires phosphor-
ylation of PKCd-Y311 and the presence of a second tyrosine
residue. Further studies will be necessary to identify the
precise role of the secondary tyrosine.
MATERIALS AND METHODS
Antibodies and reagents
Keratinocyte serum-free medium, gentamicin, and trypsin were
purchased from Life Technologies Inc (Carlsbad, CA). Antibodies for
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detection of PKCd (sc-937) and PKCa (sc-208) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-b-actin (A5441)
was purchased from Sigma (St Louis, MO). Rabbit polyclonal anti-
PKCd-P-Y311 (murine) (44–950) was obtained from BioSource
International Inc (Camarillo, CA). Horseradish peroxidase-conju-
gated sheep anti-mouse IgG (NA931) and donkey anti-rabbit IgG
(NA934) antibodies were purchased from Amersham Biosciences
(Cleveland, OH). Apigenin (no. A3145) and curcumin (no. C1386)
were obtained from Sigma. FuGENE 6 transfection reagent (no.
1814443) was purchased from Roche Diagnostics Corporation
(Indianapolis, IN). PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyra-
zolo[3,4,d]pyrimidine) is an src family kinase inhibitor. All experi-
ments were approved by the appropriate institutional board and the
study plan was conducted according to the Declaration of Helsinki
Principles.
Plasmids
The hINV reporter plasmids, encoding various lengths of hINV
promoter upstream regulatory region fused to the luciferase reporter
gene in pGL2-basic, have been described (Welter and Eckert, 1995;
Efimova et al., 1998). The PKCd tyrosine mutants are identified by
indicating the position of the mutant tyrosine (e.g., PKCd-Y52F,
PKCd-D5(Y52,64,155,187,565F)). Some of the mutants used in this study
were previously described (Blass et al., 2002) and others were
constructed as part of this study. PKCa/d refers to the chimera of the
PKCa regulatory and the PKCd catalytic domain; PKCd/a refers to the
reciprocal chimera. PKC chimeras have been used to assign domain
function of PKC isoforms (Acs et al., 1997). All PKCd constructs
have GFP fused to the PKCd C-terminus. Empty expression vector,
pEGFP-N1, was purchased from Clontech (Palo Alto, CA).
Site-directed mutagenesis of PKCd
PKCd-D5(Y52,64,155,187,565F) was used as a template for the site-
directed mutagenesis to restore mutated tyrosine residues, using the
QuikChange Site-Directed Mutagenesis Kit from Stratagene (no.
200518, La Jolla, CA). The following oligonucleotides served as
primers for mutagenesis: 50-GCCCACCATGTATCCCGAGTGGAA
GACAACG, converts phenylalanine 52 to tyrosine (bold letters); 50-
CGACGCCCACATCTACGAAGGCCGTGTTATCC, converts pheny-
lalanine 64 to tyrosine (bold letters); 50-GGCCAAGATCCACTATA
TAAAGAACCACG, converts phenylalanine 155 to tyrosine (bold
letters); 50-CTCAACAAGCAAGGCTATAAATGCAGGCAATGC, con-
verts phenylalanine 187 to tyrosine (bold letters); 50-GGACACAC
CACACTATCCCCGCGGGATCACC, converts phenylalanine 565 to
tyrosine (bold letters). Using PKCd plasmid as template, 50-GGA
CACACCACACTTTCCCCGTTGGATCACC was used to change
tyrosine 565 to phenylalanine (bold letters). Another oligonucleo-
tide, 50-GTCTGTCGGAATATTCCAGGGATTTGAG, was used to
convert Y311 to phenylalanine (bold letters). The mutations were
confirmed by DNA sequencing.
Cell culture, transfection, and hINV promoter assay
Normal human foreskin keratinocytes were grown as described
previously (Welter and Eckert, 1995). All use of human tissues
complies with federal and institutional guidelines. For plasmid DNA
transfection, third-passage keratinocytes, cultured in 35mm dia-
meter dishes, were transfected when 25% confluent. FuGENE 6
transfection reagent (12 ml) was mixed with 200ml of keratinocyte
serum-free medium, and 4 mg of plasmid DNA was added. The
mixture was incubated at room temperature for 15minutes and then
added dropwise to the cells in dishes containing 2ml of keratinocyte
serum-free medium. After 48 hours, keratinocytes were rinsed twice
with 1 phosphate-buffered saline, incubated in 100 ml of cell
culture lysis reagent (Promega, Madison, WI) for 15minutes, and
harvested by scraping. The cell lysates were assayed immediately
using a Berthold luminometer and Promega luciferase assay reagent.
Cell lysate (20ml) and 100ml of luciferin solution were reacted for
4 seconds and light output was monitored during the next
20 seconds. All assays were performed in duplicate, and each
experiment was repeated a minimum of three times. Luciferase
activity is normalized per mg of protein.
Immunoblot analysis
Total cell lysates were prepared from cultured human epithelial
keratinocytes at 48 hours post-transfection or at 24 hours after
apigenin or curcumin treatment. Cells were washed with phos-
phate-buffered saline and incubated on ice in lysis buffer (20mM
Tris-HCl pH 7.5, 150mM NaCl, 2mM Na2EDTA, 2mM EGTA, 1%
Triton X-100, 2.5mM sodium pyrophosphate, 1mM b-glycero-
phosphate, 1mM Na3VO4, 1mg ml
1 leupeptin, and 1mM PMSF)
for 5minutes. Lysates were collected, sonicated intermittently for
20 seconds, and then centrifuged at 15,000 g for 10minutes at 41C to
pellet cell debris. Protein concentrations were determined by Bio-Rad
protein assay. Equivalent amounts of protein were electrophoresed on
denaturing polyacrylamide gels and subsequently transferred to
nitrocellulose for immunoblot. The membranes were blocked and
incubated with appropriate primary and secondary antibodies, and
proteins were visualized using chemiluminescence reagents.
Microscopy
Human epidermal keratinocytes were plated onto 22 22mm
coverslips and transfected with 1 mg of plasmid encoding wild-type
or mutant PKCd-GFP. After 48 hours, keratinocytes were fixed with
3.7% paraformaldehyde in phosphate-buffered saline at room
temperature for 20minutes. After two washes with 1 phosphate-
buffered saline, the cells were mounted on glass slides with
mounting medium and the distribution of the PKCd-GFP fusion
proteins was examined by confocal fluorescence microscopy.
Subcellular fractionation
Keratinocytes were grown in 60mm diameter dishes and, when 25%
confluent, were transfected with 3mg of plasmid DNA encoding
PKCd-wt, PKCd-Y311F, PKCd-D5, or EV. At 48 hours post-transfec-
tion, cells were exposed to 50 ng TPA per ml for 60minutes.
Keratinocytes were then rinsed with 1 phosphate-buffered saline
and lysed in 150ml of buffer containing 20mM HEPES (pH 7.4),
250mM sucrose, 150mM NaCl, 0.5mM EGTA, 0.5mM EDTA, 1mM
dithiothreitol, 1mM phenylmethylsulfonyl fluoride, 8mg ml1 apro-
tinin, 20 mM leupeptin, 200mM NaVO3, and 10mM NaF. Cell lysates
were sonicated intermittently for 20 seconds and centrifuged for
1 hour at 41C. The supernatant was collected as the soluble protein
fraction. The membrane pellet was washed with 500 ml of lysis buffer
and centrifuged for 1 hour at 41C. The membrane pellet was
resuspended in 150ml of the lysis buffer containing 1% Triton
X-100. Protein concentrations were determined by Bio-Rad protein
assay. An equivalent amount of protein was electrophoresed on 10%
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polyacrylamide denaturing gels, and PKCd and involucrin levels
were assayed by immunoblot.
PKCd activity assay
Keratinocytes were transfected with 3 mg of EV or plasmid encoding
PKCd, PKCdY52F, PKCd-Y311F, PKCd-D5(Y52,64,155,187,565F), PKCd-
D6(Y52,64,155,187,311,565F), or PKCd-D4(Y64,155,187,565F). At 48 hours
post-transfection, cells were lysed in 20mM Tris-HCl (pH 7.5)
containing 150mM NaCl, 1% Triton X-100, 1mM EDTA, 1mM EGTA,
2.5mM sodium pyrophosphate, 1mM b-glycerophosphate, 1mM
sodium orthovanadate, 1mg ml1 leupeptin, 2mM phenylmethylsul-
fonyl fluoride, and 0.5mM dithiothreitol. Protein lysate (400 mg) was
precleared by mixing with 25 ml of Protein A/G PLUS-agarose beads
(Santa Cruz Biotechnology), and the suspension was rotated for
2 hours at 41C. The preparation was centrifuged at 4,000 r.p.m. for
1minute and the supernatant was incubated with 2mg of mouse
monoclonal anti-GFP antibody (ab1218) for 3 hours, followed by
incubation with 25 ml of Protein A/G PLUS-agarose beads overnight.
The suspension was then centrifuged at 4,000 r.p.m. for 1minute and
the beads were washed three times with lysis buffer and once with
kinase assay buffer (50mM Tris-HCl (pH 7.5), 10mM b-glyceropho-
sphate, 4mM dithiothreitol, 20mM MgCl2, and 0.2mM sodium
orthovanadate). The beads were resuspended in 20 ml of kinase
buffer. PKCd activity was assayed using freshly prepared immuno-
precipitate. Activity was measured using the SignaTECT Protein
Kinase C Assay System (Promega, no. 7470) according to the
manufacturer’s instructions. Biotinylated peptide Neurogranin(2843)
(AAKIQASFRGHMARKK) is used as PKC substrate in this assay. The
serine indicated by the asterisk is the target serine.
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